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In their article, Franco and Cedazo-
Minguez open the debate on why it is
difficult to translate successful preclini-
cal research in Alzheimer’s disease (AD)
mouse models into clinical practice (1).
Here, we discuss some aspects that should
be taken into account regarding the main
discrepancies that exist between the cur-
rent animal models and the disease in
humans.
The translation of findings from bench
to clinically relevant therapies is very com-
plex. In fact, despite a full preclinical
and clinical trial package, the large major-
ity of drugs with initial phases based on
translational-laboratory-based discoveries
actually fail to complete the development
process. A lack of efficacy, side-effects,
inappropriate doses, and pharmacokinetics
are just a few of the various reasons for this
failure. Furthermore, the preclinical dis-
ease models on which new drugs are tested
may not always be predictive of the effect
of the agent in the human disease state
(2). Could this be, as Franco and Cedazo-
Minguez suggest, one of the major con-
cerns in translational research in the case
of AD?
On the one hand, one of the main points
to consider is probably the fact that most
of the AD-mouse models do not present
the extensive neuronal loss observed in the
brain of AD patients. At the moment of
clinical diagnosis, most of the patients with
AD-type dementia already have a Braak
stage V or VI with a substantial synap-
tic and neuronal loss (3). Nevertheless, the
loss of synapses is the best correlate of the
cognitive impairment in patients with AD
(4, 5). The synapse loss, which predates
neuronal death in the human condition,
is present in most of these mouse mod-
els, suggesting that they may represent the
prodromal phase of the disease. Several
authors have proposed that in the human
condition, as a compensatory response, an
enlargement of remaining synapses may
occur,allowing the system to respond prop-
erly (6, 7). This could be one of the rea-
sons why progression from early-phase to
symptomatic stages in AD takes such a
long time. It has been suggested that this
“silent” period of the disease can even
last for decades (8). Therefore, many of
the therapies assayed on the AD mod-
els that are ineffective in people with the
already established pathology might pos-
sibly be effective in preventing or delay-
ing disease progression toward demen-
tia. Although none of the animal models
may represent the best option for eval-
uating novel therapeutic approaches for
mild to moderate AD cases, they might
be the first step in evaluating drugs that
could reverse the synapse loss that under-
lies the “silent” phase of the disease. In ani-
mal models, the synapse loss underlies the
memory deficits observed with the behav-
ior tasks used for testing memory func-
tion. Therefore, therapeutic approaches for
reversing memory deficits in AD-mouse
models through the enhancement of the
synaptic function and/or spine density
might be of great value for treating the
memory decline that also occurs in patients
with “mild cognitive impairment” (MCI), a
term proposed by Petersen et al. as a new
diagnostic entity for the transition between
normal aging and AD dementia (9). Ulti-
mately, since the AD drug development
mainly motivated by the amyloid hypothe-
sis had frightening results, the latest idea
is that other pathways, which are not
directly linked to Aβ, should be explored. In
this context, phosphodiesterase-inhibitors,
already on the market for other clinical
uses (10) or epigenetic drugs (11) as poten-
tial memory enhancers could be a reli-
able option. Moreover, it is also impor-
tant to note that all the AD therapies
assayed in different clinical trials that could
not continue on to subsequent phases
due to the appearance of side-effects or
those that have failed because the dose
assayed in human trials had not been
properly established, should also be care-
fully reviewed. Investing in the improve-
ment of current drugs that have already
been assayed and/or in drug-repurposing
might be of special use in the case
of AD.
On the other hand, it should be taken
into account that sporadic forms of AD
have a multifactorial origin, with many
different risk factors contributing to AD
progression. Reducing any one of them by
acting on/or improving the neural envi-
ronment of the brain of these AD-mouse
models (by antioxidants, vitamins, cogni-
tive enhancers, vasodilators, etc.) may be
sufficient for ameliorating the incipient
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FIGURE 1 | Development of the differentAD signs inTg2576 mice over time. Scheme showing the time point of main AD features apparition inTg2576 mice.
At the age of 16month, although no neuronal loss is presented in the brain of Tg2576 mice, the AD-phenotype is well established. MWM Morris water maze.
AD-phenotype of the models. Moreover,
different mice strains should be used for
modeling human-like environment factors
because the use of inbred strains with
a common genetic background, housed
in a controlled environment, eliminates
most of the variability that exists in
the human condition. Some researchers
have proposed that benefits with a new
therapeutic intervention should be demon-
strated in at least two different animal
models and replicated by independent lab-
oratories before beginning human exper-
imentation (2). In addition, it is impor-
tant to highlight that among the risk fac-
tors, aging, which is the most important
one, is not always present in the preclin-
ical studies carried out on animal models.
The overexpression of familial AD-genes in
these models accelerates the onset of the
AD-phenotype, with amyloid plaques and
synaptic deficits appearing even when the
animals are 2–4 months old. The possible
advantage of using these early models, with
their early onset of symptoms, has the dis-
advantage of compromising the age factor.
Therefore, the use of late-plaque models
(i.e., Tg2576, PDAPP, TgAPP23) for pre-
clinical studies could be more accurate than
using early plaque models (12). Figure 1
shows the main AD features developed in
Tg2576 mice (a late-plaque model) over
time; this model has been used in differ-
ent studies in our laboratory over the last
10 years.
In summary, although we agree with
most of the statements made in the review
by Franco and Cedazo-Minguez, since
animal models are indeed mandatory for
preclinical studies, we consider that in the
case of AD, the model selected (a late onset
model with an established phenotype) and
the appropriate dosage regimen may be
critical for the successful translation of
experimental drugs to humans.
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